5ENK
Compound 18
Summary for 5ENK
Entry DOI | 10.2210/pdb5enk/pdb |
Related | 5ENM |
Descriptor | Beta-secretase 1, GLYCEROL, IODIDE ION, ... (5 entities in total) |
Functional Keywords | bace, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor |
Biological source | Homo sapiens (Human) |
Cellular location | Membrane; Single-pass type I membrane protein: P56817 |
Total number of polymer chains | 1 |
Total formula weight | 50854.95 |
Authors | Lewis, H.A. (deposition date: 2015-11-09, release date: 2016-07-06, Last modification date: 2024-10-16) |
Primary citation | Wu, Y.J.,Guernon, J.,Yang, F.,Snyder, L.,Shi, J.,Mcclure, A.,Rajamani, R.,Park, H.,Ng, A.,Lewis, H.,Chang, C.,Camac, D.,Toyn, J.H.,Ahlijanian, M.K.,Albright, C.F.,Macor, J.E.,Thompson, L.A. Targeting the BACE1 Active Site Flap Leads to a Potent Inhibitor That Elicits Robust Brain A beta Reduction in Rodents. Acs Med.Chem.Lett., 7:271-276, 2016 Cited by PubMed Abstract: By targeting the flap backbone of the BACE1 active site, we discovered 6-dimethylisoxazole-substituted biaryl aminothiazine 18 with 34-fold improved BACE1 inhibitory activity over the lead compound 1. The cocrystal structure of 18 bound to the active site indicated two hydrogen-bond interactions between the dimethylisoxazole and threonine 72 and glutamine 73 of the flap. Incorporation of the dimethylisoxazole substitution onto the related aminothiazine carboxamide series led to pyrazine-carboxamide 26 as a very potent BACE1 inhibitor (IC50 < 1 nM). This compound demonstrated robust brain Aβ reduction in rat dose-response studies. Thus, compound 26 may be useful in testing the amyloid hypothesis of Alzheimer's disease. PubMed: 26985314DOI: 10.1021/acsmedchemlett.5b00432 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.11 Å) |
Structure validation
Download full validation report